ArticleCureus2024
Evaluating the Incidence of Incidental Gallbladder Carcinoma in a Tertiary Care Centre: A Retrospective Analysis in North India.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incidental Gallbladder Cancer After Cholecystectomy for Presumed Benign Biliary Disease: A Sixteen-Year Retrospective Cohort Study from a Tertiary Referral Center.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Incidental gallbladder carcinoma (IGBC) remains a significant clinical challenge, with its diagnosis often delayed due to the asymptomatic nature of the disease and its incidental discovery post-cholecystectomy. This study's aim is to calculate incidence in a high-risk, region-specific (North Indian) population and also to provide novel insights into clinical presentation as well as macroscopic and histopathological features of IGBC. Material and methods This retrospective observational study spanned four years (August 2013 to July 2016) and included a total of 3096 cases. Demographic, clinical, radiological, treatment and follow-up data were sourced from archived records. IGBC diagnoses were confirmed on formalin-fixed, paraffin-embedded tissue sections stained with hematoxylin and eosin (H&E). Results A total of 3,067 routine cholecystectomies were performed during this period, of which a total of 162 cases (18.93%) were diagnosed as gallbladder carcinoma (GBC) and 51 cases (1.74%) were identified as IGBC. The mean age was 49.8 years. Among the total IGBC cases, most patients underwent preoperative imaging of which eight cases (15.6%) showed findings on preoperative radiological evaluation suggestive of malignancy. Among these, five cases (9.8%) demonstrated subtle gallbladder wall thickening and three cases (5.8%) revealed suspicious small polypoidal lesions (less than 1 cm). Microscopy showed that majority of these tumours were well-differentiated adenocarcinomas (n=27; 52.94%), followed by moderately differentiated adenocarcinomas (n=17; 33.33%), mucinous adenocarcinomas (n=03; 5.88%), papillary adenocarcinomas (n=02; 3.92%), and neuroendocrine tumours (n=1; 1.96%). Staging revealed 26 (50.98%) cases as Stage IIA, 24 (47.0%) as Stage I, and one (1.9%) as Stage III. On follow-up, the median survival period was found to be 32 months. Conclusions Our study emphasizes the limitations of conventional imaging in detecting early-stage gallbladder cancer, and it advocated the critical importance of routine histopathological examination (HPE) of all gallbladder specimens. Additionally, our findings contribute to a growing body of evidence that suggests early-stage IGBC may offer improved survival outcomes if diagnosed timely and treated aggressively, prompting a re-evaluation of current diagnostic and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.